官方服务：
资源简介：
GVHD and final outcome.
应用场景：
创建时间：
2019-12-13
相关数据集
Chemotherapy and Unrelated Donor SCT for Blood and Immune System Cancers
Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without an HLA tissue-matched sibling and graft-versus-host disease (GVH
NIAID Data Ecosystem60
Risk factors for conjunctival aGVHD after adult allogeneic HSCT.
Risk factors for conjunctival aGVHD after adult allogeneic HSCT.
NIAID Data Ecosystem10
A clinical trial of Vedolizumab vs. placebo (dummy drug) for the prevention of intestinal Acute Graft Versus Host Disease (aGvHD), in patients undergoing allo-HSCT for a hematologic malignancy, (cancers that affect the blood and/or lymphatic system).
Main Objective: To evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free surviva
NIAID Data Ecosystem10
Combination of 5-Aza with DZNep enhance prophylactic effect for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Objective: Previous studies showed epigenetic prophylaxis could alleviate acute graft versus host disease (aGvHD) but affecting engraftment after allo-HSCT. Combination of two different epigenetic age
NIAID Data Ecosystem20
Single Center Randomized Trial of Orca-T alone versus Orca-T Plus Tacrolimus Prophylaxis in the Prevention of Acute Graft Versus Host Disease. Single Center Randomized Trial of Orca-T alone versus Orca-T Plus Tacrolimus Prophylaxis in the Prevention of Acute Graft Versus Host Disease
Twenty-four patients were randomized to receive Orca-T alone (n=12) or Orca-T plus single-agent GVHD prophylaxis (n=12) to determine if Orca-T alone was non-inferior in preventing acute GVHD. Overall
NIAID Data Ecosystem10
